Zhongsheng Ruichuang and Qilu Pharmaceutical Enter Strategic Collaboration to Advance Commercialization of RAY1225 in China

On January 16, 2026, raynovent, a controlling subsidiary of Guangdong Zhongsheng Pharmaceutical Co., Ltd., held a strategic cooperation signing ceremony with Qilu Pharmaceutical Co., Ltd. ("Qilu Pharmaceutical").Jointly Announce Innovative DrugsGLP-1/GIP Dual-Target Receptor Ultra-Long-Acting Agonist RAY1225 Injection Licensing Agreement Signed: Raynovent Authorizes Qilu Pharmaceutical Co., Ltd. for Production and Commercial Sales of RAY1225 Injection in China (including mainland China, Hong Kong, Macao, and Taiwan).Raynovent reserves all rights, ownership, and interests in the licensed intellectual property.

RAY1225 Injection is an innovative peptide drug with a novel structure independently developed by raynovent, possessing dual agonist activity for both GLP-1 and GIP receptors. Due to its excellent pharmacokinetic properties, it has the potential to be an ultra-long-acting drug administered once every two weeks. Currently, the Phase III clinical trial (REBUILDING-2 study) evaluating the safety and efficacy of RAY1225 Injection for treating obese/overweight patients in China, the Phase III clinical trial (SHINING-3) assessing the safety and efficacy of RAY1225 Injection in combination with oral hypoglycemic agents for type 2 diabetes patients compared with Semaglutide Injection, and the placebo-controlled Phase III clinical trial (SHINING-2) examining the safety and efficacy of RAY1225 Injection as monotherapy for type 2 diabetes patients have all successfully completed participant enrollment. raynovent will continue to uphold a rigorous attitude, advancing the Phase III clinical trials of RAY1225 Injection with high quality, efficiency, and scientific standards.

Qilu Pharmaceutical has rich sales experience and excellent commercialization capabilities. Relying on Qilu Pharmaceutical's comprehensive advantages such as extensive market coverage across all formats in the pharmaceutical industry and professional promotion capabilities, this lays a solid foundation for both parties to establish a strong and win-win strategic partnership.This cooperation helps to leverage raynoventThe leading product advantages of RAY1225 Injection and the strong commercialization capabilities of Qilu Pharmaceutical will further accelerate the commercialization process of RAY1225 Injection in China, effectively meeting the significant clinical demand in the country.

Under the terms of the agreement, Raynovent will receive an upfront payment and milestone payments totaling RMBRMB 100,000 million, including an upfront payment of RMB 20,000 million, development and sales milestones totaling up to RMB 80,000 million, and the right to receive double-digit royalties on net sales of the licensed product after its commercial launch. Meanwhile, Raynovent will continue to be responsible for advancing the clinical development and registration for relevant indications within the合作区域 (cooperation region).

Chen Xiaoxin, Ph.D., Vice President of Zhenzhong Pharmaceutical and Chairman of Raynovent, stated:

"We are delighted to have reached a commercialization collaboration with Qilu Pharmaceutical for RAY1225 in the Greater China region. Among numerous potential partners, we ultimately chose Qilu Pharmaceutical as the commercialization partner for RAY1225 based on its leading position in China's pharmaceutical industry and outstanding commercialization capabilities. As a leader and standout in China’s pharmaceutical field, Qilu Pharmaceutical boasts an extensively covered sales network and excellent market access capabilities."We firmly believe that, relying on the strong commercialization system of Qilu Pharmaceutical, this cooperation will help us to more efficiently"RAY1225, this innovative drug, brings a safer and more effective treatment option to the vast number of patients with obesity/overweight and diabetes."

About Raynovent

raynovent (hereinafter referred to as"Raynovent" is a Sino-foreign joint venture specializing in the research, development, and commercialization of innovative drugs for respiratory and metabolic diseases. Established in October 2018, its headquarters is located in Huangpu District, Guangzhou City, China. It is a wholly-owned subsidiary of "Guangdong Zhongsheng Pharmaceutical Co., Ltd.," a well-known A-share listed company.

Raynovent, based on its understanding and insights into the pathophysiology of respiratory and metabolic diseases, focuses on the research and development of influenza, COVID-19, avian influenza, idiopathic pulmonary fibrosis, and non-alcoholic steatohepatitis.New therapies for major diseases and public health issues such as Type 2 diabetes and weight management.

Raynovent has established multiple global first-in-class or best-in-class drug pipelines at various stages of development. The world's first oral peptidomimetic monotherapy.The 3CL protease inhibitor, Reritrelvir Tablets (Lerivo®), used for treating mild to moderate COVID-19 infections, obtained its drug registration certificate in 2023 and achieved industrialization. Compared with Pfizer's Paxlovid, Reritrelvir Tablets can be used as a single agent without the need for co-administration with Ritonavir, minimizing drug interactions and providing safer and more effective protection for high-risk COVID-19 populations, demonstrating significant clinical advantages. The world’s first influenza virus RNA polymerase PB2 inhibitor, Anorrelvir Tablets (Anriview®), for treating adult uncomplicated influenza A, received marketing approval in May 2025. Anorrelvir Tablets have shown outstanding performance across multiple key indicators, offering a new "Chinese solution" for global influenza prevention with its “rapid, potent, low-resistance” characteristics; the treatment of uncomplicated influenza in children aged 2-17 with Anorrelvir has entered Phase III clinical trials. ZSP1601, China’s first innovative drug approved for clinical treatment of MASH, is currently in Phase IIb clinical trials. RAY1225 Injection, a long-acting GLP-1/GIP dual agonist with global independent intellectual property rights for treating metabolic syndrome, has now fully launched Phase III clinical trials for obesity/overweight patients and two Phase III clinical trials for type 2 diabetes patients (SHINING-2 and SHINING-3).

About Qilu Pharmaceutical

Qilu Pharmaceutical is a pharmaceutical industry group with a patriotic spirit, innovation-driven genes, and an international perspective, and has establishedWith 11 major production bases covering 9,160 mu and over 36,000 employees, Qilu Pharmaceutical ranked third on the 2024 China Pharmaceutical Industry Top 100 list. The group has always adhered to the core values of "Great Medicine with Sincerity, Family and Country for the World," closely focusing on the public's need for a healthy and better life, providing high-quality and trustworthy medicines to the world. It has cumulatively launched over 320 products, including 79 that were the first in China or exclusively available. Its products are exported to more than 100 countries and regions worldwide, benefiting approximately 1.5 billion patients annually. The group insists on conducting "innovation with warmth," aligning with the cutting-edge of global science and technology. It has established six R&D platforms linked between China and the U.S., building a globally influential product pipeline. Currently, nearly 300 branded generics, over 20 biosimilars, and more than 80 innovative drugs are at various stages of clinical development.